2064 |
ERB-B2 RECEPTOR TYROSINE KINASE 2 |
ERBB2 |
CD340 |
HER-2 |
HER-2/neu |
HER2 |
MLN 19 |
NEU |
NGL |
TKR1 |
164870 |
3430 |
ENSG00000141736 |
OTTHUMG00000179300 |
P04626 |
RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 |
ERBB2_HUMAN |
HER2 (ERBB2/neu) |
EGFR (HER1/ERBB1)HER2 (ERBB2/neu)HER3 (ERBB3) |
EGFR (HER1/ERBB1)HER2 (ERBB2/neu)HER4 (ERBB4) |
MLN19 |
Metastatic lymph node gene 19 protein |
Proto-oncogene Neu |
Proto-oncogene c-ErbB-2 |
Tyrosine kinase-type cell surface receptor HER2 |
p185erbB2 |
CD_antigen=CD340 |
20 |
PA27844 |
RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 PRECURSOR (EC 2.7.1.112) (P185ERBB2) (C-ERBB-2) (NEU PROTO-ONCOGENE) (TYROSINE KINASE-TYPE CELL SURFACE RECEPTOR HER2) (MLN 19). [SOURCE:UNIPROT/SWISSPROT;ACC:P04626] |
Erbb2 tyrosine kinase receptor |
T14597 |
VSCN2 |
Interpro Name | Serine-threonine/tyrosine-protein kinase catalytic domain |
Interpro Type | Domain |
Interpro Short Name | Ser-Thr/Tyr_kinase_cat_dom |
Interpro Acc | IPR001245 |
Uniprot Evidence | 1: Evidence at protein level |
Human Readable Name | DRUGGABLE GENOME |
Uniprot Status | Swiss-Prot |
Human Readable Name | KINASE |
Initial Gene Query | HER2/ErbB2 |
Counted Citations from 1950-2000 | 6422 |
Target Subclass | EGFR |
Target Subclass | Kinase |
Target Main Class | Receptors |
Transmembrane Helix Count | 1 |
Target Class | Receptors |
Target Subclass | EC:2.7.10.1 |
Gene Biotype | PROTEIN_CODING |
KINASE |
TYROSINE KINASE |
DRUG RESISTANCE |
DRUGGABLE GENOME |
CLINICALLY ACTIONABLE |
antibody (inhibitory) |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Receptor protein-tyrosine kinase erbB-2 inhibitor |
Notes |
inhibitor (inhibitory) |
Evidence Type | Actionable |
combination therapy | Capecitabine + Neratinib |
Approval Status | FDA approved |
inhibitor (inhibitory) |
Response Type | conflicting |
Approval Status | Phase I |
Indication/Tumor Type | Her2-receptor positive breast cancer |
inhibitor (inhibitory) |
Mechanism of Interaction | Receptor protein-tyrosine kinase erbB-2 inhibitor |
Direct Interaction | yes |
Indication/Tumor Type | Her2-receptor positive breast cancer |
antibody (inhibitory) |
inhibitor (inhibitory) |
Trial Name | MGAH22 |
Novel drug target | Established target |
Mechanism of Interaction | Receptor protein-tyrosine kinase erbB-2 inhibitor |
antagonist (inhibitory) |
inhibitor (inhibitory) |
combination therapy | Lapatinib + Palbociclib |
combination therapy | Entinostat + Lapatinib |
combination therapy | Lapatinib + Paclitaxel |
antibody (inhibitory) |
inhibitor (inhibitory) |
Notes | Prevents dimerization of HER2 with other HER receptors |
combination therapy | Trastuzumab + Pertuzumab |
Indication/Tumor Type | Her2-receptor positive breast cancer |
inhibitor (inhibitory) |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | sensitive |
Approval Status | Preclinical - Cell culture |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Receptor protein-tyrosine kinase erbB-2 inhibitor |
Indication/Tumor Type | stomach cancer |
inhibitor (inhibitory) |
Trial Name | AC480 |
Novel drug target | Established target |
Mechanism of Interaction | Receptor protein-tyrosine kinase erbB-2 inhibitor |
n/a |
combination therapy | MM-302 + Trastuzumab |
Indication/Tumor Type | stomach cancer |
Response Type | sensitive |
antibody (inhibitory) |
combination therapy | Paclitaxel + Trastuzumab + MM-111 |
Indication/Tumor Type | stomach cancer |
Response Type | sensitive |
inhibitor (inhibitory) |
Mechanism of Interaction | Receptor protein-tyrosine kinase erbB-2 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Novel drug target | Established target |
Trial Name | ARRY-334543 |
combination therapy | trastuzumab + varlitinib |
inhibitor (inhibitory) |
Notes | |
Mechanism of Interaction | Receptor protein-tyrosine kinase erbB-2 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Receptor protein-tyrosine kinase erbB-2 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Indication/Tumor Type | breast cancer |
Response Type | sensitive |
Approval Status | Preclinical - Cell line xenograft |
inhibitor (inhibitory) |
Indication/Tumor Type | non-small cell lung carcinoma |
Response Type | sensitive |
Approval Status | Phase II |
n/a |
Combination therapy | Tipiracil,Trifluridine |
inhibitor (inhibitory) |
Mechanism of Interaction | Receptor protein-tyrosine kinase erbB-2 inhibitor |
Direct Interaction | yes |
Evidence Type | Actionable |
n/a |
Evidence Type | Actionable |
Approval Status | Phase II |
Response Type | no benefit |
inhibitor (inhibitory) |
Novel drug target | Established target |
Trial Name | INSM-18 |
Mechanism of Interaction | Receptor protein-tyrosine kinase erbB-2 inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | Receptor protein-tyrosine kinase erbB-2 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Epidermal growth factor receptor inhibitor |
Direct Interaction | yes |
Indication/Tumor Type | stomach cancer |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Receptor protein-tyrosine kinase erbB-2 inhibitor |
Notes |
inhibitor (inhibitory) |
Notes |
inhibitor (inhibitory) |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | sensitive |
Approval Status | Preclinical |
n/a |
Mechanism of Interaction | Receptor protein-tyrosine kinase erbB-2 other |
Direct Interaction | yes |
inhibitor (inhibitory) |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | sensitive |
Approval Status | Preclinical |
n/a |
Mechanism of Interaction | Receptor protein-tyrosine kinase erbB-2 other |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Receptor protein-tyrosine kinase erbB-2 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Receptor protein-tyrosine kinase erbB-2 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Trial Name | CUDC-101 |
Novel drug target | Established target |
Notes |
inhibitor (inhibitory) |
Mechanism of Interaction | Receptor protein-tyrosine kinase erbB-2 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Receptor protein-tyrosine kinase erbB-2 inhibitor |
Direct Interaction | yes |
n/a |
Combination therapy | Tipiracil,Trifluridine |
n/a |
Evidence Type | Actionable |
Approval Status | Phase II |
Response Type | predicted – sensitive |
inhibitor (inhibitory) |
Mechanism of Interaction | Epidermal growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Receptor protein-tyrosine kinase erbB-2 inhibitor |
n/a |
combination therapy | Exemestane + Seribantumab |
Indication/Tumor Type | Her2-receptor negative breast cancer |
Response Type | predicted – sensitive |
inhibitor (inhibitory) |
Mechanism of Interaction | Receptor protein-tyrosine kinase erbB-2 inhibitor |
Direct Interaction | yes |
n/a |
combination therapy | Entinostat + Lapatinib + Trastuzumab |
Indication/Tumor Type | Her2-receptor positive breast cancer |
Response Type | sensitive |
inhibitor (inhibitory) |
Mechanism of Interaction | Epidermal growth factor receptor inhibitor |
Direct Interaction | yes |
n/a |
Evidence Type | Actionable |
Approval Status | Guideline |
Response Type | sensitive |
n/a |
Evidence Type | Actionable |
Approval Status | Guideline |
Response Type | sensitive |
n/a |
combination therapy | Cisplatin + Gemcitabine + Sorafenib |
Indication/Tumor Type | invasive bladder transitional cell carcinoma |
Response Type | predicted – sensitive |
ERBB2 | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
P04626 | Uniprot Accession |
RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 | Uniprot Protein Name |
2064 | Entrez Gene Id |
Interpro Name | Serine-threonine/tyrosine-protein kinase catalytic domain |
Interpro Type | Domain |
Interpro Short Name | Ser-Thr/Tyr_kinase_cat_dom |
KINASE, DRUGGABLE GENOME |
RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 PRECURSOR (EC 2.7.1.112) (P185ERBB2) (C-ERBB-2) (NEU PROTO-ONCOGENE) (TYROSINE KINASE-TYPE CELL SURFACE RECEPTOR HER2) (MLN 19). [SOURCE:UNIPROT/SWISSPROT;ACC:P04626] | Description |
ERBB2 | Display Id |
ENSG00000141736 | Ensembl Gene Id |
Human Readable Name | DRUGGABLE GENOME |
DRUGGABLE GENOME |
2064 | Entrez Gene ID |
Initial Gene Query | HER2/ErbB2 |
Counted Citations from 1950-2000 | 6422 |
KINASE |
ERBB2 | Gene Symbol |
Target Class | Receptors |
Target Subclass | EC:2.7.10.1 |
P04626 | Uniprot Accession |
ERBB2_HUMAN | Uniprot Id |
2064 | Entrez Gene Id |
Target Subclass | EGFR |
Target Subclass | Kinase |
Target Main Class | Receptors |
2064 | CKB Entrez Id |
ERBB2 | CKB Gene Synonym |
CD340 | CKB Gene Synonym |
PA27844 | PharmGKB ID |
2064 | Entrez Gene ID |
20 | CIViC Gene ID |
DRUG RESISTANCE, CLINICALLY ACTIONABLE |
HER2 | TTD Gene Abbreviation |
T14597 | TTD Target ID |
2064 | Entrez Gene Id |
ERBB2 | MyCancerGenome Gene Symbol |
HER2 (ERBB2/neu) | MyCancerGenome Reported Gene Name |
ENSG00000141736 | Gene Symbol |
ERBB2 | Ensembl Id |
DRUGGABLE GENOME |
HER2 | Gene Symbol |
MLN19 | GENE_SYMBOL |
NEU | GENE_SYMBOL |
NGL | GENE_SYMBOL |
2064 | OncoKB Entrez Id |
CD340 | OncoKB Gene Synonym |
MLN 19 | OncoKB Gene Synonym |
HER2 | GO Gene Synonym |
MLN19 | GO Gene Synonym |
NEU | GO Gene Synonym |
TYROSINE KINASE |
ERBB2 | Gene Symbol |
CLINICALLY ACTIONABLE |
2064 | Gene ID |
CD340 | dGene Synonym |
HER-2 | dGene Synonym |
KINASE, TYROSINE KINASE |
Receptor tyrosine-protein kinase erbB-2 | Gene Name |
P04626 | UniProt ID |
KINASE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |